vs
Side-by-side financial comparison of Axos Financial, Inc. (AX) and Axsome Therapeutics, Inc. (AXSM). Click either name above to swap in a different company.
Axos Financial, Inc. is the larger business by last-quarter revenue ($392.2M vs $196.0M, roughly 2.0× Axsome Therapeutics, Inc.). Axos Financial, Inc. runs the higher net margin — 31.8% vs -14.6%, a 46.4% gap on every dollar of revenue. Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 16.1%).
Axos Financial is an American bank holding company based in Las Vegas, Nevada and is the parent of Axos Bank, a direct bank. It also offers registered investment adviser services and an electronic trading platform.
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
AX vs AXSM — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $392.2M | $196.0M |
| Net Profit | $124.7M | $-28.6M |
| Gross Margin | — | — |
| Operating Margin | — | -13.8% |
| Net Margin | 31.8% | -14.6% |
| Revenue YoY | — | 65.0% |
| Net Profit YoY | 18.5% | 61.9% |
| EPS (diluted) | $2.15 | $-0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $392.2M | — | ||
| Q4 25 | $385.1M | $196.0M | ||
| Q3 25 | $323.4M | $171.0M | ||
| Q2 25 | $321.4M | $150.0M | ||
| Q1 25 | $308.8M | $121.5M | ||
| Q4 24 | $307.9M | $118.8M | ||
| Q3 24 | $320.7M | $104.8M | ||
| Q2 24 | $290.9M | $87.2M |
| Q1 26 | $124.7M | — | ||
| Q4 25 | $128.4M | $-28.6M | ||
| Q3 25 | $112.4M | $-47.2M | ||
| Q2 25 | $110.7M | $-48.0M | ||
| Q1 25 | $105.2M | $-59.4M | ||
| Q4 24 | $104.7M | $-74.9M | ||
| Q3 24 | $112.3M | $-64.6M | ||
| Q2 24 | $104.9M | $-79.3M |
| Q1 26 | — | — | ||
| Q4 25 | 45.6% | -13.8% | ||
| Q3 25 | 46.3% | -27.0% | ||
| Q2 25 | 48.5% | -24.5% | ||
| Q1 25 | 47.9% | -46.9% | ||
| Q4 24 | 48.8% | -61.1% | ||
| Q3 24 | 49.6% | -59.8% | ||
| Q2 24 | 49.6% | -89.5% |
| Q1 26 | 31.8% | — | ||
| Q4 25 | 33.3% | -14.6% | ||
| Q3 25 | 34.7% | -27.6% | ||
| Q2 25 | 34.4% | -32.0% | ||
| Q1 25 | 34.1% | -48.9% | ||
| Q4 24 | 34.0% | -63.1% | ||
| Q3 24 | 35.0% | -61.7% | ||
| Q2 24 | 36.0% | -91.0% |
| Q1 26 | $2.15 | — | ||
| Q4 25 | $2.22 | $-0.55 | ||
| Q3 25 | $1.94 | $-0.94 | ||
| Q2 25 | $1.89 | $-0.97 | ||
| Q1 25 | $1.81 | $-1.22 | ||
| Q4 24 | $1.80 | $-1.54 | ||
| Q3 24 | $1.93 | $-1.34 | ||
| Q2 24 | $1.75 | $-1.67 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $322.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.1B | $88.3M |
| Total Assets | $29.2B | $689.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | $322.9M | ||
| Q3 25 | $2.6B | $325.3M | ||
| Q2 25 | $1.9B | $303.0M | ||
| Q1 25 | $2.0B | $300.9M | ||
| Q4 24 | $2.4B | $315.4M | ||
| Q3 24 | $2.6B | $327.3M | ||
| Q2 24 | $2.0B | $315.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $312.7M | — | ||
| Q1 25 | $377.4M | — | ||
| Q4 24 | $358.7M | — | ||
| Q3 24 | $313.5M | — | ||
| Q2 24 | $325.7M | — |
| Q1 26 | $3.1B | — | ||
| Q4 25 | $2.9B | $88.3M | ||
| Q3 25 | $2.8B | $73.7M | ||
| Q2 25 | $2.7B | $73.1M | ||
| Q1 25 | $2.6B | $53.2M | ||
| Q4 24 | $2.5B | $57.0M | ||
| Q3 24 | $2.4B | $92.9M | ||
| Q2 24 | $2.3B | $102.9M |
| Q1 26 | $29.2B | — | ||
| Q4 25 | $28.2B | $689.8M | ||
| Q3 25 | $27.4B | $669.3M | ||
| Q2 25 | $24.8B | $639.8M | ||
| Q1 25 | $24.0B | $596.7M | ||
| Q4 24 | $23.7B | $568.5M | ||
| Q3 24 | $23.6B | $561.5M | ||
| Q2 24 | $22.9B | $548.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.14× | — | ||
| Q4 24 | 0.14× | — | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-18.7M |
| Free Cash FlowOCF − Capex | — | $-18.7M |
| FCF MarginFCF / Revenue | — | -9.6% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-93.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $104.1M | $-18.7M | ||
| Q3 25 | $118.4M | $1.0M | ||
| Q2 25 | $490.3M | $-32.4M | ||
| Q1 25 | $73.7M | $-43.4M | ||
| Q4 24 | $162.5M | $-26.2M | ||
| Q3 24 | $70.8M | $-18.6M | ||
| Q2 24 | $305.5M | $-30.1M |
| Q1 26 | — | — | ||
| Q4 25 | $85.4M | $-18.7M | ||
| Q3 25 | $109.3M | $988.0K | ||
| Q2 25 | $436.1M | $-32.4M | ||
| Q1 25 | $65.1M | $-43.7M | ||
| Q4 24 | $156.4M | $-26.2M | ||
| Q3 24 | $53.0M | $-18.7M | ||
| Q2 24 | $269.5M | $-30.2M |
| Q1 26 | — | — | ||
| Q4 25 | 22.2% | -9.6% | ||
| Q3 25 | 33.8% | 0.6% | ||
| Q2 25 | 135.7% | -21.6% | ||
| Q1 25 | 21.1% | -36.0% | ||
| Q4 24 | 50.8% | -22.1% | ||
| Q3 24 | 16.5% | -17.9% | ||
| Q2 24 | 92.6% | -34.6% |
| Q1 26 | — | — | ||
| Q4 25 | 4.9% | 0.0% | ||
| Q3 25 | 2.8% | 0.0% | ||
| Q2 25 | 16.9% | 0.0% | ||
| Q1 25 | 2.8% | 0.3% | ||
| Q4 24 | 2.0% | 0.0% | ||
| Q3 24 | 5.5% | 0.1% | ||
| Q2 24 | 12.4% | 0.1% |
| Q1 26 | — | — | ||
| Q4 25 | 0.81× | — | ||
| Q3 25 | 1.05× | — | ||
| Q2 25 | 4.43× | — | ||
| Q1 25 | 0.70× | — | ||
| Q4 24 | 1.55× | — | ||
| Q3 24 | 0.63× | — | ||
| Q2 24 | 2.91× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AX
| Net Interest Income | $306.3M | 78% |
| Noninterest Income | $86.0M | 22% |
AXSM
Segment breakdown not available.
